Lupin Q2 FY2027 Sales Up 14% YoY to ₹77,855 Mn

Lupin Limited reported its unaudited financial results for the quarter ended September 30, 2026. Consolidated sales for Q2 FY2027 increased by 14.0% year-on-year to INR 77,855 Mn (₹7,785.5 Crore) from INR 68,314 Mn (₹6,831.4 Crore) in Q2 FY2026. However, EBITDA saw a decline of 10.7% to INR 21,712 Mn (₹2,171.2 Crore) and Profit After Tax (PAT) decreased by 22.2% to INR 11,553 Mn (₹1,155.3 Crore). The company highlighted strong growth in the U.S. (up 9.3%) and India (up 14.7%) markets, along with significant growth in Other Developed Markets (up 45.7%). Investment in R&D for the quarter was INR 6,181 Mn (7.9% of sales). The company received 4 ANDA and 1 NDA 505(b)(2) approvals from the U.S. FDA.